Inês Martins, PhD, managing science editor —

A Phase 1 trial in China is recruiting multiple myeloma patients who failed prior treatments to study Cellular Biomedicine’s CAR T-cell product, C-CAR088. The trial is for patients who have received at least two multiple myeloma therapies — including…

Heavily treated multiple myeloma patients included in the first four dosing groups of Cellectar Biosciences’ Phase 1 trial lived for a median of 22 months after receiving a single dose of CLR 131, a new trial update shows. While all patients in the study received CLR 131, impairing a…

Long-term maintenance treatment with Revlimid (lenalidomide) significantly improves the length of time multiple myeloma patients live without disease worsening after their first-line therapy and, in some patients, also extends overall survival, a Phase 3 trial shows. Findings from the trial were published in the study, “…

Multiple myeloma patients who are not eligible for high-dose chemotherapy and stem cell transplant significantly benefit from the addition of Darzalex (daratumumab) to the standard first-line treatment of Revlimid (lenalidomide) plus dexamethasone, a Phase 3 trial shows. The triple combination reduced the risk of disease progression or death by 45%…

Updated results from a Phase 2b clinical trial continue to support Karyopharm Therapeutics‘ investigative oral therapy selinexor (KPT-330) as a promising approach for heavily-treated multiple myeloma patients who have exhausted all approved therapies. In the trial, STORM (NCT02336815), more than a quarter of patients responded to the treatment, with responses…

The European Commission has approved the anti-CD38 antibody Darzalex (daratumumab), in combination with standard therapy, for newly diagnosed multiple myeloma patients who cannot receive a stem cell transplant. The approval is based on data from the ALCYONE Phase 3 trial (NCT02195479), where adding Darzalex to standard of care — Velcade (bortezomib), melphalan,…

Prescribing information for Kyprolis (carfilzomib) in the U.S. will now include positive survival data from the ASPIRE Phase 3 clinical trial, which found treatment significantly lowered a risk of death for patients with relapsed or refractory multiple myeloma, and extended overall survival by a median of 7.9 months. The extended label…

A Phase 1b trial testing a combination of Reolysin (pelareorep), Velcade (bortezomib) and dexamethasone in multiple myeloma patients who failed to respond to previous therapy is opening a new treatment group — one that will add Keytruda (pembrolizumab) to this mix. This extension of the ongoing REO 019 study (…

Trillium Therapeutics recently dosed the first patient in its Phase 1 clinical trial of TTI-622, a checkpoint inhibitor of the immune system being developed for the treatment of relapsed or refractory lymphoma and myeloma. Although the innate immune system is a key ally in fighting cancer, tumor cells…

Janssen recently initiated a Phase 1b/2 clinical development program to evaluate JNJ-68284528, a chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment  of relapsed or refractory multiple myeloma. The Phase 1b/2 open-label trial (NCT03548207) is scheduled to begin enrolling 84 patients later this year, following the approval…